Inflammatix, Inc. is reimagining molecular diagnostics by developing rapid point-of-care tests that aid in the diagnose of acute infections and sepsis based on our unique immune profiling technology. Approximately $10 billion / year is spent trying to diagnose acute infections, but current methods that focus on ‘finding the bug’ are too slow and are ineffective 70% of the time. In many cases, this approach leaves clinicians with no choice but to treat their patients without a complete and true understanding of their patient’s ailment. Inflammatix is developing a game-changing diagnostic test that reads the immune system and uses proprietary algorithms to generate clinically actionable and timely information on the presence, type (bacterial or viral), and severity of infection in patients. Our host response-based diagnostics pipeline includes tests for acute infection and sepsis, emerging infectious diseases, acute myocardial infarction, autoimmune diseases, and other conditions.
Product in development, is not for sale, and does not have marketing approval or clearance from regulatory authorities in any jurisdiction.